cgp-56697 has been researched along with Headache* in 1 studies
1 trial(s) available for cgp-56697 and Headache
Article | Year |
---|---|
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.
CIS43LS is a monoclonal antibody that was shown to protect against controlled. We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against. In Part B, 330 adults underwent randomization; 110 were assigned to each trial group. The risk of moderate headache was 3.3 times as high with 40 mg of CIS43LS per kilogram as with placebo.. CIS43LS was protective against Topics: Adult; Antibodies, Monoclonal, Humanized; Antimalarials; Artemether, Lumefantrine Drug Combination; Headache; Humans; Malaria, Falciparum; Mali; Plasmodium falciparum | 2022 |